Monday, September 19, 2022

Scientists identify key biomarkers that reliably predict response to immune checkpoint inhibitor therapy for melanoma

Currently, the only FDA approved biomarker for ICI melanoma treatment is the tumor mutation burden assay, but the mechanisms linking it to ICI remain unclear. However, new research now provides evidence of novel, reliable biomarkers that predict therapy response using advanced computer technology.

from Latest Science News -- ScienceDaily https://ift.tt/W73kf1Z
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Only 13 % know: The one-minute self-exam that could save young men’s lives

A new survey shows most Americans wrongly think testicular cancer is an older man's issue, despite it most commonly affecting men aged 2...